Adding the immunotherapy drug tarlatamab-dlle (Imdelltra) to durvalumab (Imfinzi) helped people with extensive-stage small cell lung cancer (SCLC) live a median of 8.4 months longer than those receiving durvalumab alone, according to a recent phase 3 study.
Extensive-stage SCLC has spread widely within the chest or to other parts of the body.
Read on to learn more details about the study and its findings.
Maintenance treatment is given after initial treatment has helped control cancer. Its goal is to keep the cancer from worsening for as long as possible.
Tarlatamab is a type of immunotherapy called a bispecific T-cell engager. It works by bringing immune cells called T cells close to lung cancer cells, helping the immune system attack the cancer.
The U.S. Food and Drug Administration (FDA) has approved tarlatamab for adults with extensive-stage SCLC whose cancer worsened during or after platinum-based chemotherapy.
Durvalumab is another type of immunotherapy. It blocks a protein called PD-L1, helping the immune system recognize and attack cancer cells.
In the trial, researchers randomly assigned 282 people to receive tarlatamab plus durvalumab and 281 people to receive durvalumab alone. Everyone had extensive-stage SCLC that hadn’t worsened after initial treatment with durvalumab and chemotherapy.
The study measured overall survival and progression-free survival beginning when participants started maintenance treatment.
Researchers found:
These results suggest that the combination may help some people with extensive-stage SCLC live longer without their cancer worsening.
For people living with extensive-stage SCLC, these findings offer hope for a treatment approach that may help extend survival and delay cancer progression.
However, the results don’t mean that the combination is appropriate for everyone. Although tarlatamab is already FDA-approved for certain people with extensive-stage SCLC, its use alongside durvalumab as first-line maintenance treatment remains investigational.
If you’re living with extensive-stage SCLC, consider asking your oncology team what maintenance treatments are currently available, whether these findings may apply to you, and whether participating in a clinical trial might be an option.
Your care team can also help you understand the potential benefits and risks of different treatments.
Get updates directly to your inbox.
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.